DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation" report to their offering.
Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable auto-immune disease that affects the joints, and is characterized by synovial inflammation and hyperplasia. It occurs when a number of aberrant cell signaling events trigger chronic inflammation of the synovium - the soft tissue of the joint - leading to pain, joint stiffness, and eventually deformity and disability.
With the disease affecting 0.3-1.0% of the global population, the societal and economic costs of RA are substantial. The large target patient population and the relatively high annual cost of therapy have resulted in a crowded, highly lucrative market.
Treatment options have improved and diversified substantially over the past two decades, largely owing to the advent of biologics. Despite this, considerable unmet needs remain within RA. Consequently, opportunities for future drug developments remain significant, particularly for first-in-class innovation, which is the area most likely to produce substantial clinical advances.
Key Topics Covered:
1 Tables & Figures
2 Executive Summary
2.1 A Crowded, Competitive Market, with Significant Unmet Needs Remaining
2.2 Early-Stage Pipeline Offers Greatest Promise for First-in-Class Innovation
2.3 Cytokine and Cytokine Receptors, as well as Protein Kinases, Largely Dominate First-in-Class Pipeline Products
3 The Case for Innovation
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Development Remains Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation
3.6 Report Guidance
4 Clinical and Commercial Landscape
4.1 Disease Overview
4.2 Disease Symptoms
4.3 Epidemiology
4.4 Etiology
4.5 Pathophysiology
4.6 Co-morbidities and Complications
4.7 Diagnosis
4.8 Disease Progression
4.9 Treatment Options and Treatment Algorithm
4.10 Overview of Marketed Products in Rheumatoid Arthritis
5 Assessment of Pipeline Product Innovation
5.1 Rheumatoid Arthritis Pipeline by Stage of Development, Molecule Type and Molecular Target
5.2 Comparative Distribution of Programs between the Rheumatoid Arthritis Market and Pipeline by Therapeutic Target Family
5.3 First-in-Class Programs Targeting Novel Molecular Targets
6 Signaling Network, Disease Causation and Innovation Alignment
6.1 Complexity of Signaling Networks in Rheumatoid Arthritis
6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration
6.3 First-in-Class Matrix Assessment
7 First-in-Class Target Evaluation
7.1 Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 5 (CD40)
7.2 Pipeline Programs Targeting Non-Receptor Tyrosine-Protein Kinase TYK2 (TYK2)
7.3 Pipeline Programs Targeting IL-10 and IL-18
7.4 Pipeline Programs Targeting 72 kDa Type IV Collagenase (MMP2)
7.5 Pipeline Programs Targeting P2X Purinoceptor 7 (P2RX7)
7.6 Pipeline Programs Targeting Protein Kinase C Theta Type (PRKCQ)
7.7 Pipeline Programs Targeting C-C Motif Chemokine 4 (CCL4) and C-C Motif Chemokine 5 (CCL5)
7.8 Pipeline Programs Targeting C-X-C Motif Chemokine 10 (CXCL10) and C-X-C Motif Chemokine 13 (CXCL13)
8 Strategic Consolidations
8.1 Industry-Wide First-in-Class Deals
8.2 Licensing Deals
8.3 Co-development Deals
8.4 First-in-Class Programs Not Involved in Licensing or Co-development Deals
9 Appendix
For more information about this report visit http://www.researchandmarkets.com/research/35tfg6/frontier_pharma
Related Topics: Pharmaceuticals, Musculoskeletal Disorders Drugs
